Zollinger‑Ellison Disease (Gastrinoma‑Associated)
Overview
Zollinger‑Ellison disease (ZED) is a rare, malignant or semi‑malignant condition in which one or more gastrin‑producing tumors (gastrinomas) arise, most often in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to secrete massive amounts of gastric acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption.
Although classified as a type of functional pancreatic neuroendocrine tumor, ZED is distinguished by its association with the hereditary syndrome multiple endocrine neoplasia type 1 (MEN‑1) in roughly 20‑30 % of cases.
- Incidence: 0.5–2 cases per million people per year worldwide.
- Age: Most patients are diagnosed between 30 and 60 years; however, cases have been reported in children and the elderly.
- Gender: Slight male predominance (≈55 % male).
- Geography: No major regional variations; cases are reported globally.
Because the disease is rare, many patients experience a diagnostic delay of 2–5 years, often due to the nonspecific nature of early symptoms.
Symptoms
Symptoms result from hyperacidity and tumor effects. The severity varies with tumor size, location, and whether the disease is sporadic or part of MEN‑1.
Gastrointestinal Manifestations
- Refractory Peptic Ulcers: Deep, multiple ulcers in the duodenum or jejunum that do not heal with standard therapy.
- Abdominal Pain: Burning or gnawing pain, often worsened by meals.
- Diarrhea: Occurs in 40–60 % of patients; can be watery, fatty (steatorrhea), or both due to acid inactivation of pancreatic enzymes.
- Gastroesophageal Reflux Disease (GERD): Persistent heartburn from excess acid.
- Nausea & Vomiting: May be related to ulcer complications or gastric outlet obstruction.
Systemic Manifestations
- Weight Loss: Due to malabsorption and chronic diarrhea.
- Fatigue & Weakness: Consequence of anemia, electrolyte disturbances, or nutrient deficiencies.
- Electrolyte Imbalance: Low potassium (hypokalemia) and low magnesium (hypomagnesemia) from chronic diarrhea.
- Osteopenia/Osteoporosis: Long‑standing acid excess can impair calcium absorption.
Signs of Tumor Spread (if metastatic)
- Abdominal mass or fullness.
- Jaundice (if liver metastases compress bile ducts).
- Bone pain (if bone metastases).
Causes and Risk Factors
Zollinger‑Ellison disease is caused by a somatic mutation that leads to autonomous gastrin secretion. The two major pathways are:
1. Sporadic Gastrinomas
- Most common (≈70–80 %); arise de novo in pancreatic or duodenal neuroendocrine cells.
- Associated with somatic mutations in the MEN1 gene, CDKN1B, or TP53 in a minority of cases.
2. MEN‑1 Associated Gastrinomas
- Inherited autosomal‑dominant disorder caused by germline mutations in the MEN1 tumor suppressor gene.
- Patients often develop multiple endocrine tumors (parathyroid, pituitary, pancreatic).
- Up to 30 % of ZED patients have MEN‑1, and up to 25 % of MEN‑1 patients develop a gastrinoma.
Risk Factors
- Family history of MEN‑1 or ZED.
- Known germline MEN1 mutation.
- Previous history of pancreatic or duodenal neuroendocrine tumors.
- Chronic H. pylori infection does **not** cause ZED, but can co‑exist and worsen ulcer disease.
Diagnosis
Diagnosing ZED requires a combination of clinical suspicion, laboratory testing, imaging, and sometimes endoscopic procedures.
1. Laboratory Tests
- Fasting Serum Gastrin Level: A level > 1000 pg/mL (or > 10× upper limit of normal) in the presence of gastric acid hypersecretion is highly suggestive. Even moderate elevations (≥ 200 pg/mL) are significant when accompanied by low gastric pH.
- Gastric pH Measurement: A pH < 2 confirms hyperacidity.
- Secretin Stimulation Test: An increase in gastrin ≥ 120 pg/mL after IV secretin strongly supports ZED (used when baseline gastrin is equivocal).
- Other labs: CBC, electrolytes, calcium, vitamin D, and kidney function to assess complications.
2. Imaging Studies
- Triple‑phase Contrast CT Scan (abdomen/pelvis): Detects primary tumors and liver metastases with 70–80 % sensitivity.
- Magnetic Resonance Imaging (MRI) with MRCP: Helpful for small pancreatic lesions and liver lesions; higher soft‑tissue resolution.
- Somatostatin Receptor Scintigraphy (SRS) – Octreoscan®: Uses radiolabeled octreotide; can locate gastrinomas < 1 cm and assess metastatic disease.
- 68Ga‑DOTATATE PET/CT: Currently the most sensitive functional imaging modality (sensitivity ≈ 90 %).
- Endoscopic Ultrasound (EUS): Excellent for detecting small (< 2 cm) pancreatic lesions and allows fine‑needle aspiration (FNA) for histology.
3. Endoscopic Evaluation
- Upper Endoscopy (EGD): Identifies multiple duodenal/jejunal ulcers, erosions, and can obtain biopsies to rule out H. pylori or malignancy.
- Double‑Balloon Enteroscopy: Allows visualization of deep small‑bowel ulcers when conventional EGD is insufficient.
Diagnostic Criteria (Summary)
- Elevated fasting gastrin level (> 1000 pg/mL) with gastric pH < 2, or
- Elevated gastrin with a positive secretin stimulation test, plus
- Imaging evidence of a gastrin‑secreting tumor (CT, MRI, EUS, or 68Ga‑DOTATATE PET).
Treatment Options
Management aims to (1) control acid hypersecretion, (2) eradicate or reduce tumor burden, and (3) monitor for recurrence or metastasis.
Acid‑Suppressive Therapy (First‑Line)
- Proton Pump Inhibitors (PPIs): High‑dose omeprazole 60 mg bid, pantoprazole 80 mg bid, or equivalent. PPIs normalize gastric pH, heal ulcers, and relieve diarrhea.
- Histamine‑2 Receptor Antagonists (H2RAs): Cimetidine or ranitidine may be added if PPIs are insufficient, but PPIs are preferred due to stronger acid control.
- Long‑term PPI use requires monitoring for hypomagnesemia, vitamin B12 deficiency, and osteoporosis.
Surgical Management
- Curative Resection: Enucleation or segmental resection of isolated gastrinomas (especially duodenal) when feasible. Lymphadenectomy is recommended because up to 50 % have regional node involvement.
- Debulking Surgery: For metastatic disease, removing > 90 % of tumor burden can improve symptom control and survival.
- Pancreaticoduodenectomy (Whipple): Considered for large pancreatic head tumors or when multiple duodenal lesions are present.
- Pre‑operative localization with 68Ga‑DOTATATE PET and intra‑operative ultrasound improves surgical success.
Medical Oncology (Non‑Surgical Cases)
- Somatostatin Analogs: Octreotide LAR or lanreotide; reduce gastrin secretion and may stabilize tumor growth. Helpful for unresectable or metastatic gastrinomas.
- Targeted Therapy: Everolimus (mTOR inhibitor) has shown disease‑stabilization in pancreatic neuroendocrine tumors, including gastrinomas.
- Chemotherapy: Limited role; streptozocin‑based regimens or capecitabine‑temozolomide may be used in aggressive metastatic disease.
- Peptide‑Receptor Radionuclide Therapy (PRRT): 177Lu‑DOTATATE for tumors with high somatostatin‑receptor expression; improves progression‑free survival (NEJM 2021).
Liver‑Directed Therapies (for hepatic metastases)
- Radiofrequency ablation (RFA) or microwave ablation.
- Trans‑arterial chemo‑embolization (TACE) or radio‑embolization (Y‑90).
Supportive Care & Lifestyle Adjustments
- Low‑fat, low‑fiber diet to reduce diarrhea.
- Avoid NSAIDs, aspirin, and alcohol (they exacerbate ulcer disease).
- Calcium and vitamin D supplementation if on long‑term PPIs.
- Regular bone‑density screening.
Living with Zollinger‑Ellison Disease (gastrinoma‑associated)
While ZED is chronic, most patients achieve good quality of life with proper treatment.
Daily Management Tips
- Medication Adherence: Take PPIs exactly as prescribed; never skip doses.
- Scheduled Follow‑up: Serum gastrin and imaging every 6–12 months; more frequent if you have MEN‑1.
- Nutrition:
- Eat small, frequent meals to avoid overwhelming acid production.
- Limit high‑acid foods (citrus, tomato, chocolate) if they trigger symptoms.
- Consider a dietitian for tailored low‑fat, high‑protein plans when diarrhea is problematic.
- Hydration & Electrolytes: Replace lost fluids with oral rehydration solutions, especially during diarrheal episodes.
- Bone Health: Weight‑bearing exercise, calcium 1,200 mg/day, vitamin D 800–1,000 IU/day, and periodic DEXA scans.
- Monitor for Complications:
- Watch for new abdominal pain, black stools, or sudden weight loss.
- Report any signs of hypocalcemia (muscle cramps, tingling).
Psychosocial Support
- Join support groups (e.g., Neuroendocrine Tumor (NET) Patient Network).
- Consider counseling to address anxiety related to chronic illness and cancer risk.
Prevention
Because ZED is largely driven by genetic mutations, primary prevention is limited. However, the following measures can reduce disease burden and complications:
- Genetic Counseling: If you have a family history of MEN‑1, seek testing; early identification allows surveillance before tumor development.
- Avoid Gastric Irritants: Chronic use of NSAIDs, excessive alcohol, or smoking can worsen ulcer disease and should be minimized.
- Screen High‑Risk Individuals: Annual fasting gastrin levels and abdominal imaging for confirmed MEN‑1 carriers, starting in adolescence.
- Prompt Treatment of H. pylori: While not a cause of ZED, eradication lowers background ulcer risk.
Complications
If untreated or inadequately controlled, ZED can lead to serious health problems:
- Refractory Peptic Ulcer Perforation: Can cause peritonitis, requiring emergent surgery.
- Gastrointestinal Bleeding: From ulcer erosion into vessels.
- Malabsorption & Nutrient Deficiencies: Especially iron, calcium, vitamin B12, leading to anemia and osteoporosis.
- Metastatic Disease: Liver, lymph nodes, bone, or lung spread in ~30–40 % of patients at diagnosis.
- Electrolyte Imbalance: Chronic diarrhea → hypokalemia, hypomagnesemia, metabolic alkalosis.
- Neuroendocrine Tumor Syndromes: In MEN‑1, concurrent hyperparathyroidism or pituitary adenomas may complicate management.
- Reduced Survival: Median survival for untreated metastatic ZED is ~3–5 years; with modern multimodal therapy, 5‑year survival exceeds 80 % for localized disease and 50 % for metastatic disease (source: SEER database, 2022).
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with medication.
- Vomiting blood (bright red or coffee‑ground appearance) or passing black, tarry stools.
- Signs of perforated ulcer: sudden rigid abdomen, fever, or shoulder pain.
- Profound dizziness, fainting, or rapid heart rate suggesting severe bleeding or electrolyte crisis.
- Severe, persistent diarrhea leading to dehydration (dry mouth, scant urine, dizziness).
- Sudden new onset of shortness of breath, chest pain, or swelling of the legs (possible tumor‑related pulmonary embolism or liver failure).
Prompt medical attention can be life‑saving.
References:
- Mayo Clinic. Zollinger‑Ellison syndrome. Accessed May 2024.
- National Cancer Institute. Pancreatic Neuroendocrine Tumors. 2023.
- American College of Gastroenterology. ACG Clinical Guideline: Management of Gastric Acid‑Related Disorders. 2022.
- World Health Organization. Neuroendocrine Tumours Fact Sheet. 2023.
- Strosberg J, et al. “Phase 3 Trial of 177Lu‑DOTATATE for Mid‑Gut Neuroendocrine Tumors.” NEJM. 2021;384:1105‑1115.
- SEER Cancer Statistics Review, 1975‑2022. National Cancer Institute. 2024.